Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 10/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 5/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5223518 | 1.00 | SPHK2 (0.47) | SPHK2SPHK1NR1H4HDAC8HDAC6 | |
| SCHEMBL5224224 | 1.00 | SPHK2 (0.47) | SPHK2SPHK1NR1H4HDAC8HDAC6 | |
| SCHEMBL5221700 | 0.76 | SPHK1 (0.66) | SPHK2SPHK1SMN1; SMN2 | |
| SCHEMBL5221713 | 0.76 | SPHK1 (0.66) | SPHK2SPHK1SMN1; SMN2 | |
| SCHEMBL5223353 | 0.75 | SPHK2 (0.45) | SPHK2SPHK1SMN1; SMN2 | |
| SCHEMBL5227257 | 0.75 | SPHK1 (0.52) | SPHK2SPHK1HDAC6SMN1; SMN2 | |
| SCHEMBL5227166 | 0.75 | SPHK1 (0.52) | SPHK2SPHK1SMN1; SMN2 | |
| SCHEMBL5225958 | 0.74 | SMN1; SMN2 (0.59) | SMN1; SMN2 | |
| SCHEMBL5225149 | 0.73 | SMN1; SMN2 (0.61) | SMN1; SMN2 | |
| SCHEMBL12905219 | 0.72 | CHRM2 (0.43) | NR1H4HDAC8HDAC6HDAC1HDAC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771449-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-04-11 | — | — | EP | claimed |
| WO-2006011043-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-20060019998-A1 | Histamine-3 receptor antagonist | PFIZER INC | 2006-01-26 | — | — | US | claimed |
| EP-1771449-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006011043-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060019998-A1 | Histamine-3 receptor antagonist | PFIZER INC | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019998-A1 | Histamine-3 receptor antagonist | HRH3, HRH4, HRH2 | SPHK2 1144/4885SPHK1 943/4885NR1H4 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.